Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3Mix is a triple antibiotic paste used in dentistry for Lesion Sterilization and Tissue Repair (LSTR). Originally developed by Hoshino et al., the standard formulation typically consists of a combination of ciprofloxacin, metronidazole, and minocycline. In clinical practice, a 'Modified 3Mix' is often used, which replaces minocycline with clindamycin or cefaclor to prevent tooth discoloration. The paste is applied topically to the pulp or root canal system of necrotic teeth, particularly in pediatric dentistry for primary molars, to achieve profound disinfection of the endodontic space and periradicular tissues. It works by targeting a broad spectrum of endodontic pathogens, including gram-positive and gram-negative bacteria as well as obligate and facultative anaerobes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3Mix.